Oncology Billing
Maximize your reimbursements with oncology-specialized billing. We handle 2026 CPT updates, radiation therapy coding restructuring, medication reimbursement, and code reduction audits for your practice.
Oncology billing is the most complex and highest-risk discipline in healthcare revenue cycle management. A single consultation can include an assessment and management (A/M) visit, multiple chemotherapy infusions in a precise sequence, supportive drug therapies, and prior authorization that must be obtained before treatment begins. High-cost drug regimens, expedited authorizations, constant updates to CPT codes, and intense scrutiny from insurers make oncology billing particularly demanding.
With 28% of specialty drug claims reimbursed at least 8% below the wholesale acquisition cost by 2026, and with commercial insurers increasingly reducing the cost of A/M services through automated algorithms, oncology practices face a critical situation due to the pressure on reimbursements. The Fair Price Maximum (FPM) provisions of the Reducing Inflation Act (RRIF) add further complexity, with several cancer therapies expected to be added to the FPM list by 2027. Independent practices are particularly vulnerable: 75% of oncology practices surveyed report an increase in cost reductions for E/M services over the past year.
At MedMaxbill, Inc., we offer comprehensive oncology billing services designed to manage these complexities on your behalf. Our team of certified billing specialists understands the specific revenue cycle requirements of oncology practices, from chemotherapy sequencing and medication reimbursement to radiation therapy coding and denial management, ensuring your practice receives every dollar earned while maintaining full regulatory compliance in 2026 and beyond.
The 2026 Oncology Billing Landscape: Critical Updates
1. Restructuring Coding in Radiation Oncology
The 2026 CPT update consolidated the long-standing radiation therapy delivery codes into three complexity-level codes: 77402 (simple), 77407 (intermediate), and 77412 (complex), grouping services that were previously billed separately. CMS adjusted the prices for these codes to reflect the new structure, but many private insurers did not update their rates. The result: a 30–40% decrease in revenue for some independent radiation oncology clinics during the first quarter of 2026, posing an existential threat to community radiation oncology, according to Dr. Todd Doyle of OneOncology. More than two-thirds of radiation oncologists surveyed reported reimbursement cuts of 10% or more.
2. Chemotherapy and Infusion Coding Hierarchy
Oncology billing follows strict coding hierarchy rules: chemotherapy must be coded before therapeutic infusions, which are coded before hydration services. Each requires accurate documentation of start and end times to support time-based CPT codes (96413, 96415, 96417). Incorrect coding or lack of time documentation is one of the most common causes of avoidable denials.
3. Drug Reimbursement and Pressure from the Purchase and Billing Model
Under Medicare’s purchase and billing model, oncology clinics purchase and administer high-cost therapies—including chemotherapy, biologics, immunotherapy, and CAR-T cell therapy—and seek reimbursement at the average selling price (ASP) plus 6% for Part B drugs. Accurate selection of the J code, correct reporting of the dosage unit, and proper use of the JW modifier for single-use vial drug waste are essential for obtaining full reimbursement. In 2026, 28% of claims were reimbursed at least 8% below the WAC, and the MFP provisions of the Reducing Inflation Act are expected to significantly impact reimbursement complexity beginning in 2027.
4. Increased Downclassification of Evaluation and Management (E/M) Visits
A joint survey by LUGPA and the Community Cancer Alliance revealed that 75% of cancer practices report an increase in downclassification of E/M visits compared to the previous year, due to insurer-driven algorithms that downclassify Level 4-5 visits without clinical review. Eighty-five percent of practices report that they are frequently required to submit medical records during appeals, and one practice that reviewed 100 downclassified records found that 98 were correctly coded from the outset. This administrative burden diverts resources from patient care.
5. Medication Site Neutrality and Payment Disparities
CMS continues to address the significant payment disparity for chemotherapy administration between clinics and outpatient hospitals. CPT code 96413 (chemotherapy administration, up to 1 hour) is paid at $199.36 in the office setting compared to $331.69 in the outpatient hospital setting, representing an increase of approximately 178% in the hospital. CMS has expressed concern about the financial incentive that drives more patients to seek care at hospitals and continues to explore location-neutral policies.
6. HOPPS and Program 340B Payment Adjustments
CMS finalized a 2.6% increase in the Hospital Outpatient Prospective Payment System (HOPPS) conversion factor for 2026 ($91,415 for hospitals that meet OQR requirements). The Program 340B drug discount remains in effect, with a 0.5% reduction in the HOPPS conversion factor, and CMS has indicated that a larger adjustment (such as 2%) could begin in 2027.
The Most Costly Oncology Billing Errors
Errors in Chemotherapy Sequencing and Time Documentation
Oncology billing follows strict hierarchical rules: chemotherapy codes (96401–96417) must be sequenced before therapeutic infusion codes (96365–96368), which in turn are sequenced before hydration codes (96360–96361). Lack of information regarding start/finish times or sequencing errors result in denials that can delay payment of high-value claims.
J-Code Errors and Drug Reimbursement
Incorrect selection of the HCPCS J-code, incorrect dosage units, lack of JW modifiers for drug waste, or lack of documentation of medical necessity for off-label treatments result in underpayments or denials for high-cost medications.
Billing in Radiation Oncology and Insurer Payment Gaps
Many commercial insurers have not updated their rates to reflect the 2026 CPT restructuring, resulting in 30-40% underpayments for the same treatment.
Reclassification of Evaluation and Management (E/M) Consultations
Insurers are using automated algorithms to reduce Level 4-5 E/M consultations to Level 3. 75% of oncology consultations report an increase in reclassification, and one consultation that reviewed 100 reclassified records found that 98 were correctly coded from the outset.
Failure to Obtain Prior Authorization
Chemotherapy regimens, biologics, immunotherapy, and targeted agents typically require prior authorization. Deficiencies in authorization are among the leading causes of claim denials in oncology.
Our Comprehensive Oncology Billing Services
Chemotherapy and Infusion Coding
Our certified coders apply the correct administration hierarchy, time-based CPT codes for intravenous infusion services, and ensure that concurrent and sequential drug administrations are accurately recorded.
Drug Reimbursement and Billing Management
We manage high-cost drug claims with accurate HCPCS J-code selection, correct dosage unit reporting, compliant use of the JW modifier for drug waste, and supporting documentation of medical necessity.
Radiation Oncology Billing
We manage the restructured 2026 CPT codes (77402, 77407, 77412), ensuring accurate reporting for treatment planning (77261–77263), simulation, physics services, image guidance, and weekly treatment management.
Evaluation and Management (E/M) Coding and Defense Against Coding Reduction
Our coders ensure accurate E/M level selection according to AMA guidelines and provide comprehensive documentation support to defend against insurer coding reduction audits.
Prior Authorization Management
We manage prior authorizations for chemotherapy regimens, biologics, immunotherapy, targeted agents, and advanced radiation techniques.
Denial and Appeal Management
Each denied claim is reviewed and appealed with supporting documentation, including medication administration records, time logs, and letters of medical necessity.
MFP and Drug Reimbursement Compliance
We track medications included in the MFP and help healthcare facilities prepare for the increasing complexity of reimbursement in 2027.
Reports and analytics
We offer real-time revenue cycle management (RCM) dashboards that cover collections, denial rates, drug billing metrics, and payer specific trends.
Why MedMaxbill for Oncology Billing?
Specialized oncology expertise:
Our team understands chemotherapy sequencing, drug reimbursement, and coding in radiation oncology—areas where generic billing companies often fall short.
Prepared for 2026 compliance:
We stay abreast of CPT 2026 updates, radiation therapy coding restructuring, changes to MFP drug reimbursement, and evolving code reduction patterns by insurers.
Drug reimbursement expertise:
We manage J-code selection, dose validation, JW modifier usage, and ASP reconciliation to protect reimbursement for high-value drugs.
Payment recovery in radiation oncology:
We help recover lost revenue due to payment gaps from commercial insurers created by the CPT 2026 restructuring.
E/M audit defense:
Our E/M benchmarking and documentation support help prevent and appeal code reductions by insurers, protecting your complex practice revenue.
Dedicated support:
You will have access to a dedicated account manager who understands your practice and is available to answer questions and provide updates.
Partner with MedMaxbill for Oncology Billing Success
Oncology billing requires a specialized approach. With the 2026 CPT updates, radiation coding restructuring, changes to MFP drug reimbursement, the increasing reduction of E/M coding, and high-cost drug claims, generalist billing firms often lose significant revenue and expose clinics to the risk of regulatory noncompliance.
At MedMaxbill, we combine industry expertise, advanced technology, and continuous monitoring to ensure your oncology clinic maximizes revenue and maintains regulatory compliance in 2026 and beyond.
Partner with MedMaxbill, Inc. and enjoy the peace of mind that comes with expert oncology billing services. Let us manage the complexities of billing so you can focus on what matters most: providing exceptional oncology care.
